1. Advances in Dry Eye

3. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States.

4. DED: One of the Most Common Reasons People Seek Eye Care

5. The Pathogenesis of DED

6. The Pathogenesis of DED

7. The Pathogenesis of DED

8. The Pathogenesis of DED

9. The Pathogenesis of DED

10. Etiological Subtypes

11. Multifactorial DED: Pathology Cycle

12. CASE: Barbara Initial Presentation

13. DED and the Asymptomatic Patient

14. CASE: Barbara Recognizing the Red Flags

15. Early Diagnosis Is Critical Potential Consequences of Untreated DED

16. Know the Risk Factors

17. Know the Risk Factors Systemic Conditions

18. Signs and Symptoms

19. Stepwise Approach to Diagnosis

20. Assessing a Patient for DED

21. Diagnostic Tests

22. Diagnostic Tests (cont)

23. Diagnostic Tests (cont)

24. Follow-up Diagnostic Testing

25. CASE: Barbara (cont) Initial Evaluation

26. CASE: Barbara Next Steps in Evaluation

27. Patient Education Environmental Modifications

28. Assessing Comorbidities

29. Treating DED The Primary Goal Is Improving QOL

30. Accurate Assessment of Severity Is Challenging

31. Stepwise Treatment Approach

32. Stepwise Treatment Approach (cont)

33. Tailoring Treatment Evaporative Subtype

34. Tailoring Treatment Topical Anti-inflammatory Agents

35. Tailoring Treatment (cont) Topical Anti-inflammatory Agents

36. Tailoring Treatment Sjögren’s Syndrome

37. CASE: Barbara Follow-up Diagnostic Testing

38. CASE: Barbara Treatment Considerations

39. Concluding Remarks

40. Abbreviations

41. Abbreviations (cont)